title: Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy.
abstract: Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years' duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.
authors: Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors: Nathan C
authors: NC
authors: Steinle
authors: Naina
authors: N
authors: Gupta
authors: Alex
authors: A
authors: Yuan
authors: Rishi P
authors: RP
authors: Singh
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002387:Cataract Extraction; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002908:Chronic Disease; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D006801:Humans; D008297:Male; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012074:Remission Induction; D012293:Rifampin / Q000008:administration & dosage*
chemical_list: D019384:Nucleic Acid Synthesis Inhibitors; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D012293:Rifampin